KB-1193

Milatuzumab

×
Please enable JavaScript in your browser to complete this form.
12195
Home » Antibodies » Milatuzumab

Background of Milatuzumab

Milatuzumab, also known as hLL1 or IMMU-115, is a humanized monoclonal antibody that targets a specific epitope of the CD74 molecule expressed on monocytes, macrophages, and B cells. Currently, Milatuzumab is being investigated as an immunotherapeutic candidate for the treatment of multiple myeloma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia (CLL).

Specifications

Catalog NumberKB-1193
Antibody NameMilatuzumab
IsotypeHuman IgG1,kappa
FC MuationsWild Type
TargetCD74
Species ReactivityHuman
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationELISA
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage.
Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;
Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Ong GL, Goldenberg DM, Hansen HJ, Mattes MJ: Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology. 1999, 98: 296-302. 10.1046/j.1365-2567.1999.00868.x.
  2. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S, Goldenberg DM: CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007, 13: 5556s-5563s. 10.1158/1078-0432.CCR-07-1167.
Please enable JavaScript in your browser to complete this form.